TAA

Affiliations

• 2013-present, Member, Molecular Biology Institute

• 2013-present, Member, Jonsson Comprehensive Cancer Center (JCCC)

• 2013-present, Member, California NanoSystems Institute

• 2014-present, Member, Broad Stem Cell Research Center

• 2014-present, Member, Medical Scientist Training Program Admissions Committee

• 2017-present, Member Researcher, Parker Institute for Cancer Immunotherapy

• 2018-present, Co-Director, JCCC Tumor Immunology Program

• 2019-present, Associate Professor (by courtesy), Department of Chemical and

• Biomolecular Engineering

• 2021-present, Mentor, NIH Maximizing Access to Research Careers (MARC) Program

University of California, Los Angeles, Assistant Professor of Chemical and Biomolecular Engineering. July 2013-June 2019

Harvard Society of Fellows. Junior Fellow, July 2011-June 2013

Harvard Medical School, Department of Systems Biology. Visiting Research Fellow,

September 2011-June 2013

Seattle Children’s Research Institute, Center for Immunity and Immunotherapies. Research Scientist, January-August 2011

California Institute of Technology, Department of Chemical Engineering. Graduate

Researcher, September 2005-December 2010

Merck & Co., Merck Manufacturing Division, Vaccine Technology and Engineering. Chemical Engineer, July 2004-August 2005

Research Interests

The Chen Laboratory is focused on applying synthetic biology and biomolecular engineering techniques to develop robust cell-based therapies for otherwise intractable diseases. We are particularly interested in engineering multi-functional T cells that can accurately identify and effectively eliminate tumor cells, in part by overcoming the various defense mechanisms associated with cancers and their microenvironments. Bispecific chimeric antigen receptor (CAR)-T cells developed in our laboratory is being tested in the clinic, and current projects include the development of next-generation CAR-T cells with enhanced specificity, reduced toxicity, and the ability to overcome tumor-associated immunosuppression.

Biography

Dr. Yvonne Chen is an Associate Professor of Microbiology, Immunology, and Molecular Genetics at the University of California, Los Angeles. Prior to joining UCLA in 2013, Dr. Chen was a Junior Fellow in the Harvard Society of Fellows. She received her B.S. in Chemical Engineering from Stanford University and her Ph.D. in Chemical Engineering from the California Institute of Technology.  She performed postdoctoral research at the Seattle Children’s Research Institute and the Department of Systems Biology at Harvard Medical School. The Chen lab’s work on engineering next-generation T-cell therapies for cancer has been recognized by the NIH Director’s Early Independence Award, the NSF CAREER Award, the Hellman Fellowship, the ACGT Young Investigator Award in Cell and Gene Therapy for Cancer, the Mark Foundation Emerging Leader Award, and the Cancer Research Institute Lloyd J. Old STAR Award. Dr. Chen is also a Member Researcher in the Parker Institute for Cancer Immunotherapy.

創立安肽生醫與公司願景

沈三泰博士於2017年12月創立安肽生醫科技（股）公司，目前擔任公司董事長兼執行長。公司的主要目標是開發新一代的癌症免疫治療抗體藥物/蛋白質藥物，而經營的方式是以公司的研發團隊（包括有抗體開發、細胞功能測試、前臨床動物試驗、臨床規劃、生醫AI等）所建立的技術平台，開發本公司智財專屬的治療用抗體藥物或蛋白質藥物，於藥物開發初期或者臨床試驗早期，尋找國內外藥廠專利授權與共同開發。

本公司於去年COVID-19疫情爆發初期，決定以所建立的合成人源抗體庫與篩選平台，投入新型冠狀肺炎病毒的抗原快篩檢測與中和抗體藥物的開發，為防疫工作盡一份心力。我們於一個月內開發可以檢驗病毒N蛋白的抗體配對，並與台康及寶齡富錦成立「寶安康聯盟」共同參與防疫工作，兩個月時完成Vstrip抗原快篩檢測試劑開發並送件TFDA審核；而中和抗體藥物的開發為今天的演講主題。

個人簡介 Biography

沈三泰先生畢業於美國德州西南醫學中心生醫博士學程，授業於Professor Johann Deisenhofer (1987 Nobel Laureate in Chemistry) ，學習蛋白質的晶體結構研究。先前分別畢業於國立臺灣大學化學系與生化科學研究所碩士班，畢業後旋進入中央研究院擔任研究助理，後因工作表現優異被擢升為正職研究人員，爾後獲公費留職留薪出國進修博士學位，回國後敘職服務於中央研究院及短暫服務於國家衛生研究院兩年。創業前，於學研單位工作近30年。

林淑菁博士現任聯合生物製藥(股)公司(聯生藥；UBP) 執行長暨總經理以及董事。林博士亦為UBI集團內多家公司的董事之一。在2019年1月加入聯生藥前，林博士為聯亞生技開發(股)公司 (UBIA) 企業發展執行副總經理，負責公司策略規劃以及募資等相關業務。

林博士自1999年加入UBI集團，從負責各項研發專案計畫的研究員逐步晉升至承擔企業發展重要責任的高階主管。林博士參與UBI集團在亞洲地區成長茁壯的每一階段。林博士為UBI集團中第一位參與人源化抗體平台 (monoclonal antibody humanization)的科學家/研究員，並帶領研發團隊建立單株抗體藥物開發平台，更將UB-421抗體進行擬人化、建立高表達細胞株、製程開發，進而推展至人體臨床一期、二期。林博士於UBIA的任職期間，帶領研發團隊申請取得11項政府研究計畫獎助，推動三株單株抗體候選藥物從初期開發至進入臨床試驗。

林淑菁博士畢業於台大植物病理學系，取得台大動物所博士學位後至中央研究院進行博士後研究，並以首席作者在國際科學期刊發表8篇科學論文。於1998年獲得中研院傑出博士後研究員獎的榮譽。

劉博士在生技、製藥以及特用化學品等產業中有三十年的產品開發、製程開發及製造的經驗。回台創立台康生技前，劉博士曾擔任日本生技新藥研發公司AnGes, Inc.美國分公司的營運長及總經理。

2002年，劉博士加入AnGes, Inc. 擔任產品管理的副總經理，並於2004-2010年間擔任AnGes在德國慕尼黑的合資企業Avontec GmbH的監督委員會副主席。在AnGes任期之前，劉博士曾在GenVec、Novartis、W.R.Grace & Co.以及Halcon SD等公司擔任各項管理及專業職務，領導產品和製程的開發。

劉博士擁有美國哥倫比亞大學化學工程和應用化學博士學位，以及國立台灣大學化學工程學士學位。

Shih-Hsien Chuang, Ph.D. Dr. Chuang received his PhD degree in Medicinal Chemistry from National Tsing Hua University in 2005. He joined DCB and started his career in drug discovery since 2006. As a principal investigator in institute of pharmaceutics, Dr. Chuang led several drug discovery projects especially on oncology field. For example, the Nek2/Hec1 inhibitor against advanced refractory solid tumors collaborated with Taivex Therapeutics was in Phase I clinical trial. Besides, Dr. Chuang also focused on developing novel technology platforms such as next generation antibody-drug conjugates (ADC) and proteolysis targeting chimera (PROTAC). Dr. Chuang had over 20 papers published in peer-reviewed journals.